002332.SHE Zhejiang Xianju Pharmaceutical Co Ltd
- Market cap
- CNY 8.81B
- P/E
- 19.0x
- P/B
- 1.49x
- ROE
- 9.5%
- Dividend yield
- 4.56%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002332.SHE undervalued?
Graham number002332.SHE trades 12.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Xianju Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Xianju Pharmaceutical Co Ltd yet.
Zhejiang Xianju Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers cortical steriod, gynecology and family planning, respiratory, and dermatological drugs, as well as anaesthetic and muscle relaxants; and active pharmaceutical ingredients and intermediates. It is also involved in the provision of contract development and…
Full company profileZhejiang Xianju Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Xianju Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.50B | 2.85B | 3.62B | 3.71B | 4.02B | 4.36B | 4.38B | 4.12B | 4.00B | 3.76B | 3.90B |
| Gross Profit | 1.27B | 1.59B | 2.13B | 2.23B | 2.22B | 2.51B | 2.51B | 2.15B | 2.26B | 2.30B | 2.41B |
| Operating Income | 176M | 298M | 431M | 543M | 597M | 759M | 879M | 646M | 678M | 490M | 654M |
| EBITDA | 284M | 432M | 605M | 697M | 817M | 857M | 866M | 816M | 835M | 763M | 676M |
| Net Income | 146M | 207M | 301M | 410M | 505M | 619M | 749M | 563M | 397M | 450M | 563M |
| EPS | 0.16 | 0.23 | 0.33 | 0.45 | 0.51 | 0.63 | 0.76 | 0.57 | 0.40 | 0.45 | 0.57 |
| Balance Sheet | |||||||||||
| Total Assets | 3.62B | 5.13B | 5.44B | 5.82B | 6.84B | 6.72B | 6.74B | 6.99B | 7.00B | 7.26B | 7.08B |
| Total Liabilities | 1.38B | 2.75B | 2.73B | 2.77B | 2.26B | 1.78B | 1.23B | 1.16B | 1.11B | 1.18B | 1.14B |
| Shareholders' Equity | 2.23B | 2.35B | 2.63B | 2.94B | 4.44B | 4.83B | 5.46B | 5.79B | 5.84B | 6.04B | 5.90B |
| Cash & Short-term Investments | 488M | 911M | 892M | 1.03B | 1.44B | 1.77B | 1.72B | 1.66B | 1.38B | 1.20B | 1.21B |
| Total Debt | 541M | 1.92B | 1.77B | 1.77B | 1.18B | 739M | 344M | 446M | 39.3M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 156M | 167M | 193M | 520M | 789M | 676M | 609M | 595M | 399M | 247M | - |
| Capital Expenditure | 97.1M | 123M | 169M | 262M | 118M | 267M | 283M | 235M | 208M | 209M | 156M |
| Free Cash Flow | 58.8M | 44.2M | 24.0M | 257M | 671M | 409M | 327M | 361M | 191M | 38.4M | 663M |
| Ratios | |||||||||||
| ROE | 6.6% | 8.8% | 11.5% | 14.0% | 11.4% | 12.8% | 13.7% | 9.7% | 6.8% | 7.5% | 9.5% |
| ROA | 4.0% | 4.0% | 5.5% | 7.0% | 7.4% | 9.2% | 11.1% | 8.1% | 5.7% | 6.2% | 8.0% |
| Net Profit Margin | 5.8% | 7.2% | 8.3% | 11.1% | 12.6% | 14.2% | 17.1% | 13.7% | 9.9% | 12.0% | 14.4% |
| Debt to Equity | 0.24x | 0.82x | 0.67x | 0.60x | 0.27x | 0.15x | 0.06x | 0.08x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Xianju Pharmaceutical Co Ltd dividends
- Dividend yield
- 4.56%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 89.3%
- Ex-dividend date
- Sep 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 402M | 0.41 | 89.3% |
| 2024 | CNY 298M | 0.30 | 75.1% |
| 2023 | CNY 300M | 0.30 | 53.2% |
| 2022 | CNY 148M | 0.15 | 19.8% |
| 2021 | CNY 148M | 0.15 | 24.0% |
| 2020 | CNY 91.7M | 0.09 | 18.2% |
| 2019 | CNY 59.6M | 0.06 | 14.5% |
| 2018 | CNY 125M | 0.14 | 41.6% |
| 2017 | CNY 157M | 0.17 | 76.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on May 18, 2017.
Who owns Zhejiang Xianju Pharmaceutical Co Ltd
- Insiders 26.19%
- Institutions 6.32%
- Public & others 67.50%
- Shares outstanding 989M
- Free float 758M
Zhejiang Xianju Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Xianju Pharmaceutical Co Ltd
- Ticker
- 002332.SHE
- ISIN
- CNE100000K64
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jan 12, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,209
- Fiscal year end
- December
- Address
- No. 15, Fengxi West Road, Xianju, China, 317306
- Phone
- 86 57 68773 2810
- Website
- xjpharma.com
About Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers cortical steriod, gynecology and family planning, respiratory, and dermatological drugs, as well as anaesthetic and muscle relaxants; and active pharmaceutical ingredients and intermediates. It is also involved in the provision of contract development and manufacturing organization; contract manufacturing organization; technical; technology development; and inspection and testing services. The company was founded in 1972 and is headquartered in Xianju, China.
Zhejiang Xianju Pharmaceutical Co Ltd management
5- Mr. Weihua JinGM & Director · born 1975
- Ms. Yao Hua WangChief Financial Officer · born 1971
- Mr. Wangwei ZhangDeputy GM & Secretary · born 1982
- Mr. Carlo CartasegnaDeputy General Manager · born 1959
- Mr. Wen Hui ZouDeputy General Manager · born 1977